Author:
Miyazawa Yoshiyuki,Koike Hidekazu,Oka Daisuke,Kawamura Hidemasa,Kubo Nobuteru,Miyasaka Yuhei,Onishi Masahiro,Syuto Takahiro,Sekine Yoshitaka,Matsui Hiroshi,Ohno Tatsuya,Suzuki Kazuhiro
Abstract
Abstract
Background
The quality of life of patients is an important consideration when selecting treatments for localized prostate cancer (PCa). We retrospectively compared sexual function after robot-assisted radical prostatectomy (RARP) and carbon-ion radiotherapy (CIRT) using propensity score matching.
Methods
In total, 127 Japanese PCa patients treated with RARP and 190 treated with CIRT monotherapy were evaluated. We evaluated the Expanded Prostate Cancer Index Composite (EPIC) score before treatment and 12 and 24 months after treatment. After propensity score matching, data from 101 patients from each group were analyzed. The study protocol was approved by the Institutional Review Board of Gunma University Hospital (no. IRB2020-050, 1839).
Results
After propensity score matching, the mean EPIC sexual function summary scores in the RARP and CIRT groups were 46.4 and 48.2, respectively. At 12 and 24 months after treatment, these scores were 27.9 (39.9% decrease) and 28.2 (39.2% decrease) in the RARP group and 41.4 (14.1% decrease) and 41.6 (13.7% decrease) in the CIRT group, respectively. Both groups demonstrated significantly decreased scores after 12 and 24 months of treatment compared to before treatment (all p < 0.05). At 12 and 24 months, the sexual function summary score was significantly higher in the CIRT group than in the RARP group (p < 0.001).
Conclusions
There was a smaller decrease in the EPIC sexual function score in the CIRT group than in the RARP group. These results provide useful information for treatment decision-making of Japanese PCa patients.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. A systematic analysis for the global burden of Disease Study. JAMA Oncol. 2018;4(11):1553–68. https://doi.org/10.1001/jamaoncol.2018.2706.
2. Cancer Cancer Registry and Statistics. Cancer mortality and incidence. Cancer Information Service, National Cancer Center, Japan. http://ganjoho.jp/reg_stat/statistics/dl/index.html.
3. Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or Radiotherapy for prostate Cancer. N Engl J Med. 2023;388(17):1547–58. https://doi.org/10.1056/NEJMoa2214122.
4. Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, et al. Medium-term outcomes of active surveillance for localized prostate cancer. Eur Urol. 2013;64:981–7. https://doi.org/10.1016/j.eururo.2013.02.020.
5. Klotz L. Active surveillance, quality of life, and cancer-related anxiety. Eur Urol. 2013;64:37–9. https://doi.org/10.1016/j.eururo.2013.01.023.